Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/24/2025

Treatment for Cannabis Use Disorder

Understanding the Clinical Entities

  • The American Psychiatric Association describes cannabis use disorder as affecting approximately 10% of chronic cannabis users, characterized by clinically significant impairment including using more cannabis than intended and difficulty cutting back 4, 3
  • Uncomplicated cannabis dependence refers to physiological and psychological dependence without severe comorbidities, and both conditions respond to identical treatment strategies 1

First-Line Treatment Algorithm

  • The first-line treatment for cannabis use disorder and uncomplicated cannabis dependence is short-duration psychosocial support modeled on motivational principles, specifically brief interventions (5-30 minutes) incorporating individualized feedback and advice on reducing or stopping cannabis use, with follow-up offered 1, 2
  • Brief psychosocial support includes individualized feedback on cannabis consumption patterns, advice on reducing or stopping cannabis use, and offer of follow-up monitoring 1

Managing Cannabis Withdrawal

  • Withdrawal should be undertaken in a supportive environment with regular monitoring, and no specific medication is routinely recommended for cannabis withdrawal 1, 2
  • Symptomatic relief may be achieved with medications targeting specific symptoms (e.g., anxiolytics for agitation, sleep aids for insomnia) during the 1-2 week withdrawal period 1, 2
  • Withdrawal symptoms typically occur within 24-72 hours after cessation and include irritability, restlessness, anxiety, sleep disturbances, appetite changes, and abdominal pain 4, 3, 2

Pharmacotherapy Considerations

  • Dexamphetamine should NOT be offered for treatment of cannabis use disorders 1, 2

Referral Criteria

  • Refer for specialist assessment when patients fail to respond to short-duration psychological support in non-specialized settings, significant comorbid mental health disorders are present, polysubstance use complicates the clinical picture, or severe withdrawal symptoms develop requiring close monitoring 1, 2

Critical Pitfalls to Avoid

  • Never use dexamphetamine for cannabis use disorders—this is explicitly contraindicated 1, 2
  • Do not use cannabinoid agonist replacement in low-dose users (below thresholds specified above) 2
  • Monitor closely for depression or psychosis during withdrawal, which requires specialist consultation 1, 2